The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Synopsis
The global Personalizing Cancer Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Personalizing Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Personalizing Cancer Drugs.
Report Scope
The Personalizing Cancer Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Personalizing Cancer Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Personalizing Cancer Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company (Partial List):
- Bayer
- GlaxoSmithKline
- Novartis
- Sanofi
- Pfizer
- Amgen
- Merck
- Bristol-Myers Squibb
- Celgene Corporation
- Ariad Pharmaceuticals
- Eli Lilly
- Hoffmann-La Roche
- Boehringer Ingelheim
- Johnson and Johnson
- Teva Pharmaceuticals
Segment by Type
- Immunotherapy
- Targeted Therapy
- Chemotherapy
- Hormone Therapy
- Others
Segment by Application
- Breast Cancer
- Blood Cancer
- Gastrointestinal Cancer
- Prostate Cancer
- Skin Cancer
- Lung Cancer
- Others
By Region
- North America (United States, Canada)
- Europe (Germany, France, U.K., Italy, Netherlands)
- Asia-Pacific (China, Japan, South Korea, China Taiwan, Southeast Asia, India)
- Latin America, Middle East & Africa (Latin America, Mexico, Brazil, Turkey)
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Personalizing Cancer Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Personalizing Cancer Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Immunotherapy
1.2.3 Targeted Therapy
1.2.4 Chemotherapy
1.2.5 Hormone Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Personalizing Cancer Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Breast Cancer
1.3.3 Blood Cancer
1.3.4 Gastrointestinal Cancer
1.3.5 Prostate Cancer
1.3.6 Skin Cancer
1.3.7 Lung Cancer
1.3.8 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Personalizing Cancer Drugs Market Perspective (2019-2030)
2.2 Personalizing Cancer Drugs Growth Trends by Region
2.2.1 Global Personalizing Cancer Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Personalizing Cancer Drugs Historic Market Size by Region (2019-2024)
2.2.3 Personalizing Cancer Drugs Forecasted Market Size by Region (2025-2030)
2.3 Personalizing Cancer Drugs Market Dynamics
2.3.1 Personalizing Cancer Drugs Industry Trends
2.3.2 Personalizing Cancer Drugs Market Drivers
2.3.3 Personalizing Cancer Drugs Market Challenges
2.3.4 Personalizing Cancer Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Personalizing Cancer Drugs Players by Revenue
3.1.1 Global Top Personalizing Cancer Drugs Players by Revenue (2019-2024)
3.1.2 Global Personalizing Cancer Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Personalizing Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Personalizing Cancer Drugs Revenue
3.4 Global Personalizing Cancer Drugs Market Concentration Ratio
3.4.1 Global Personalizing Cancer Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Personalizing Cancer Drugs Revenue in 2023
3.5 Personalizing Cancer Drugs Key Players Head office and Area Served
3.6 Key Players Personalizing Cancer Drugs Product Solution and Service
3.7 Date of Enter into Personalizing Cancer Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Personalizing Cancer Drugs Breakdown Data by Type
4.1 Global Personalizing Cancer Drugs Historic Market Size by Type (2019-2024)
4.2 Global Personalizing Cancer Drugs Forecasted Market Size by Type (2025-2030)
5 Personalizing Cancer Drugs Breakdown Data by Application
5.1 Global Personalizing Cancer Drugs Historic Market Size by Application (2019-2024)
5.2 Global Personalizing Cancer Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Personalizing Cancer Drugs Market Size (2019-2030)
6.2 North America Personalizing Cancer Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Personalizing Cancer Drugs Market Size by Country (2019-2024)
6.4 North America Personalizing Cancer Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Personalizing Cancer Drugs Market Size (2019-2030)
7.2 Europe Personalizing Cancer Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Personalizing Cancer Drugs Market Size by Country (2019-2024)
7.4 Europe Personalizing Cancer Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Personalizing Cancer Drugs Market Size (2019-2030)
8.2 Asia-Pacific Personalizing Cancer Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Personalizing Cancer Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Personalizing Cancer Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Personalizing Cancer Drugs Market Size (2019-2030)
9.2 Latin America Personalizing Cancer Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Personalizing Cancer Drugs Market Size by Country (2019-2024)
9.4 Latin America Personalizing Cancer Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Personalizing Cancer Drugs Market Size (2019-2030)
10.2 Middle East & Africa Personalizing Cancer Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Personalizing Cancer Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Personalizing Cancer Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Bayer
11.1.1 Bayer Company Detail
11.1.2 Bayer Business Overview
11.1.3 Bayer Personalizing Cancer Drugs Introduction
11.1.4 Bayer Revenue in Personalizing Cancer Drugs Business (2019-2024)
11.1.5 Bayer Recent Development
11.2 GlaxoSmithKline
11.2.1 GlaxoSmithKline Company Detail
11.2.2 GlaxoSmithKline Business Overview
11.2.3 GlaxoSmithKline Personalizing Cancer Drugs Introduction
11.2.4 GlaxoSmithKline Revenue in Personalizing Cancer Drugs Business (2019-2024)
11.2.5 GlaxoSmithKline Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Personalizing Cancer Drugs Introduction
11.3.4 Novartis Revenue in Personalizing Cancer Drugs Business (2019-2024)
11.3.5 Novartis Recent Development
11.4 Sanofi
11.4.1 Sanofi Company Detail
11.4.2 Sanofi Business Overview
11.4.3 Sanofi Personalizing Cancer Drugs Introduction
11.4.4 Sanofi Revenue in Personalizing Cancer Drugs Business (2019-2024)
11.4.5 Sanofi Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Personalizing Cancer Drugs Introduction
11.5.4 Pfizer Revenue in Personalizing Cancer Drugs Business (2019-2024)
11.5.5 Pfizer Recent Development
11.6 Amgen
11.6.1 Amgen Company Detail
11.6.2 Amgen Business Overview
11.6.3 Amgen Personalizing Cancer Drugs Introduction
11.6.4 Amgen Revenue in Personalizing Cancer Drugs Business (2019-2024)
11.6.5 Amgen Recent Development
11.7 Merck
11.7.1 Merck Company Detail
11.7.2 Merck Business Overview
11.7.3 Merck Personalizing Cancer Drugs Introduction
11.7.4 Merck Revenue in Personalizing Cancer Drugs Business (2019-2024)
11.7.5 Merck Recent Development
11.8 Bristol-Myers Squibb
11.8.1 Bristol-Myers Squibb Company Detail
11.8.2 Bristol-Myers Squibb Business Overview
11.8.3 Bristol-Myers Squibb Personalizing Cancer Drugs Introduction
11.8.4 Bristol-Myers Squibb Revenue in Personalizing Cancer Drugs Business (2019-2024)
11.8.5 Bristol-Myers Squibb Recent Development
11.9 Celgene Corporation
11.9.1 Celgene Corporation Company Detail
11.9.2 Celgene Corporation Business Overview
11.9.3 Celgene Corporation Personalizing Cancer Drugs Introduction
11.9.4 Celgene Corporation Revenue in Personalizing Cancer Drugs Business (2019-2024)
11.9.5 Celgene Corporation Recent Development
11.10 Ariad Pharmaceuticals
11.10.1 Ariad Pharmaceuticals Company Detail
11.10.2 Ariad Pharmaceuticals Business Overview
11.10.3 Ariad Pharmaceuticals Personalizing Cancer Drugs Introduction
11.10.4 Ariad Pharmaceuticals Revenue in Personalizing Cancer Drugs Business (2019-2024)
11.10.5 Ariad Pharmaceuticals Recent Development
11.11 Eli Lilly
11.11.1 Eli Lilly Company Detail
11.11.2 Eli Lilly Business Overview
11.11.3 Eli Lilly Personalizing Cancer Drugs Introduction
11.11.4 Eli Lilly Revenue in Personalizing Cancer Drugs Business (2019-2024)
11.11.5 Eli Lilly Recent Development
11.12 Hoffmann-La Roche
11.12.1 Hoffmann-La Roche Company Detail
11.12.2 Hoffmann-La Roche Business Overview
11.12.3 Hoffmann-La Roche Personalizing Cancer Drugs Introduction
11.12.4 Hoffmann-La Roche Revenue in Personalizing Cancer Drugs Business (2019-2024)
11.12.5 Hoffmann-La Roche Recent Development
11.13 Boehringer Ingelheim
11.13.1 Boehringer Ingelheim Company Detail
11.13.2 Boehringer Ingelheim Business Overview
11.13.3 Boehringer Ingelheim Personalizing Cancer Drugs Introduction
11.13.4 Boehringer Ingelheim Revenue in Personalizing Cancer Drugs Business (2019-2024)
11.13.5 Boehringer Ingelheim Recent Development
11.14 Johnson and Johnson
11.14.1 Johnson and Johnson Company Detail
11.14.2 Johnson and Johnson Business Overview
11.14.3 Johnson and Johnson Personalizing Cancer Drugs Introduction
11.14.4 Johnson and Johnson Revenue in Personalizing Cancer Drugs Business (2019-2024)
11.14.5 Johnson and Johnson Recent Development
11.15 Teva Pharmaceuticals
11.15.1 Teva Pharmaceuticals Company Detail
11.15.2 Teva Pharmaceuticals Business Overview
11.15.3 Teva Pharmaceuticals Personalizing Cancer Drugs Introduction
11.15.4 Teva Pharmaceuticals Revenue in Personalizing Cancer Drugs Business (2019-2024)
11.15.5 Teva Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest IT & Electronics Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
